Alzheimer’s Disease/Dementia News

“Is it all worth it?” reads the title of the Reddit post from an international medical graduate community. I wake up to these posts ever so frequently; I think to myself and slide the notification away.

Hearing loss was linked to a higher risk for dementia, and this risk was greater among people who did not use a hearing aid than those who did, a recent study in JAMA Otolaryngology – Head and Neck Surgery found.

Sleep fragmentation, rather than sleep duration or self-reported sleep quality, in early midlife was associated with worse executive function, fluency and cognition more than a decade later, according to research in Neurology.

In a cohort of older adults, those with the highest percentage of high-density lipoprotein cholesterol had a 27% higher risk of incident dementia, with the risk higher for those aged 75 years and older, according to a study.

Some of the most-viewed stories on Healio Psychiatry over the past year highlighted the FDA designating an at-home depression treatment as a breakthrough device as well as the transformative power of psychedelics.

Bristol Myers Squibb and Karuna Therapeutics Inc. announced a definitive merger agreement that includes Karuna’s lead asset, a muscarinic receptor agonist to treat schizophrenia and Alzheimer’s disease psychosis.

The FDA has cleared for marketing “the world’s first” cloud-based software for clinical analysis of neuromelanin-sensitive MRI scans, according to a press release from the manufacturer.

A clinical-stage biopharmaceutical company has announced positive findings from the exploratory SHAPE phase 2 clinical trial to evaluate fosgonimeton in those with Parkinson’s disease dementia and dementia with Lewy bodies.

AbbVie Inc. has acquired Cerevel Therapeutics and its pipeline of clinical stage and preclinical neuroscience candidates in development to address conditions such as Parkinson’s disease, schizophrenia and mood disorders.

Small HDL particles play a significant role in the prevention of Alzheimer’s disease, and an inherited gene present in one in four people hinders its production in the brain, increasing risk for cognitive decline, a speaker reported.